Literature DB >> 15492502

Cytokine overexpression and constitutive NFkappaB in cancer.

Tao Lu1, George R Stark.   

Abstract

The NFkappaB family of transcription factors, central mediators of immune responses, are also involved in oncogenesis. Loss of regulation of the normally latent NFkappaB contributes importantly to the deregulated growth, resistance to apoptosis and propensity to metastasize observed in many cancers. Thus, pathways for activation of NFkappaB are promising targets for new agents that may help to prevent or treat cancer. We find that the abnormal secretion of multiple cytokines that activate NFkappaB by binding to cell-surface receptors is one of the major causes of constitutive NFkappaB activity in cancer. A novel finding is that the latent form of TGFbeta, secreted by some of these cells, can activate NFkappaB. To understand the basis of this abnormal cytokine secretion, we are using forward genetic methods to identify specific causative mutations in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492502

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  32 in total

Review 1.  Use of forward genetics to discover novel regulators of NF-kappaB.

Authors:  Tao Lu; George R Stark
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

2.  The tumor suppressor protein menin inhibits NF-κB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma.

Authors:  Ding Gang; Hua Hongwei; Liu Hedai; Zhang Ming; Huang Qian; Liao Zhijun
Journal:  Mol Biol Rep       Date:  2012-12-06       Impact factor: 2.316

3.  Novel Serine 176 Phosphorylation of YBX1 Activates NF-κB in Colon Cancer.

Authors:  Matthew Martin; Laiqing Hua; Benlian Wang; Han Wei; Lakshmi Prabhu; Antja-Voy Hartley; Guanglong Jiang; Yunlong Liu; Tao Lu
Journal:  J Biol Chem       Date:  2017-01-11       Impact factor: 5.157

4.  Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer.

Authors:  Jing Wu; Coral Omene; Jerzy Karkoszka; Maarten Bosland; Jonathan Eckard; Catherine B Klein; Krystyna Frenkel
Journal:  Cancer Lett       Date:  2011-05-13       Impact factor: 8.679

5.  Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression.

Authors:  Jin Chen; Feng-Ling Wang; Wei-Dong Chen
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

6.  Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Authors:  Baisakhi Raychaudhuri; Yulong Han; Tao Lu; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-05-04       Impact factor: 4.130

7.  NF-kappaB controls growth of glioblastomas/astrocytomas.

Authors:  Denise Smith; Takeshi Shimamura; Stephanie Barbera; Bruce E Bejcek
Journal:  Mol Cell Biochem       Date:  2007-09-09       Impact factor: 3.396

8.  Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.

Authors:  Paolo Onori; Sharon DeMorrow; Eugenio Gaudio; Antonio Franchitto; Romina Mancinelli; Julie Venter; Shelley Kopriva; Yoshiyuki Ueno; Domenico Alvaro; Jennifer Savage; Gianfranco Alpini; Heather Francis
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

9.  An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.

Authors:  Lyudmila G Burdelya; Vadim I Krivokrysenko; Thomas C Tallant; Evguenia Strom; Anatoly S Gleiberman; Damodar Gupta; Oleg V Kurnasov; Farrel L Fort; Andrei L Osterman; Joseph A Didonato; Elena Feinstein; Andrei V Gudkov
Journal:  Science       Date:  2008-04-11       Impact factor: 47.728

Review 10.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.